| Description | Vandetanib Fumarate is an orally available tyrosine kinase inhibitor. Vandetanib Fumarate works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a lesser extent VEGFR-1, which are important targets in thyroid cancer (TC). |
| Synonyms | HSDB 8198, Zactima, Caprelsa, ZD 6474, Vandetanib |
| molecular weight | 591.43 |
| Molecular formula | C26H28BrFN4O6 |
| CAS | 338992-00-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, Benvenga S, Antonelli A. Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther. 2015 Jul 3;9:3459-70. doi: 10.2147/DDDT.S72495. eCollection 2015. Review. PubMed PMID: 26170630; PubMed Central PMCID: PMC4498730. 2. Cooper MR, Yi SY, Alghamdi W, Shaheen DJ, Steinberg M. Vandetanib for the treatment of medullary thyroid carcinoma. Ann Pharmacother. 2014 Mar;48(3):387-94. doi: 10.1177/1060028013512791. Epub 2013 Nov 14. Review. PubMed PMID: 24259657. 3. Fallahi P, Ferrari SM, Baldini E, Biricotti M, Ulisse S, Materazzi G, Miccoli P, Antonelli A. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. Expert Rev Anticancer Ther. 2016 Nov;16(11):1109-1118. Epub 2016 Sep 30. Review. PubMed PMID: 27650489. 4. De Luca A, D'Alessio A, Maiello MR, Gallo M, Bevilacqua S, Frezzetti D, Morabito A, Perrone F, Normanno N. Vandetanib as a potential treatment for breast cancer. Expert Opin Investig Drugs. 2014 Sep;23(9):1295-303. doi: 10.1517/13543784.2014.942034. Epub 2014 Aug 4. Review. PubMed PMID: 25089348. |